{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T20:00:24Z","timestamp":1774468824904,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,4,9]],"date-time":"2022-04-09T00:00:00Z","timestamp":1649462400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,4,9]],"date-time":"2022-04-09T00:00:00Z","timestamp":1649462400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s40744-022-00445-w","type":"journal-article","created":{"date-parts":[[2022,4,9]],"date-time":"2022-04-09T10:02:50Z","timestamp":1649498570000},"page":"919-933","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Responses to Ixekizumab in Male and Female Patients with Psoriatic Arthritis: Results from Two Randomized, Phase 3 Clinical Trials"],"prefix":"10.1007","volume":"9","author":[{"given":"Lihi","family":"Eder","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-Peter","family":"Tony","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satish","family":"Odhav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva Galindez","family":"Agirregoikoa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariusz","family":"Korkosz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Schwartzman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aubrey Trevelin","family":"Sprabery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda M.","family":"Gellett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"So Young","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clinton C.","family":"Bertram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexis","family":"Ogdie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,9]]},"reference":[{"issue":"1","key":"445_CR1","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/j.1529-8019.2008.01215.x","volume":"22","author":"DD Gladman","year":"2009","unstructured":"Gladman DD. Psoriatic arthritis. Dermatol Ther. 2009;22(1):40\u201355.","journal-title":"Dermatol Ther"},{"issue":"10","key":"445_CR2","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMra1505557","volume":"376","author":"CT Ritchlin","year":"2017","unstructured":"Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376(10):957\u201370.","journal-title":"N Engl J Med"},{"issue":"1","key":"445_CR3","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","volume":"76","author":"PJ Mease","year":"2017","unstructured":"Mease PJ, van der Heijde D, Ritchlin CT, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017;76(1):79\u201387.","journal-title":"Ann Rheum Dis"},{"issue":"10086","key":"445_CR4","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1016\/S0140-6736(17)31429-0","volume":"389","author":"P Nash","year":"2017","unstructured":"Nash P, Kirkham B, Okada M, et al. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet. 2017;389(10086):2317\u201327.","journal-title":"Lancet"},{"issue":"4","key":"445_CR5","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1136\/annrheumdis-2012-201357","volume":"72","author":"L Eder","year":"2013","unstructured":"Eder L, Thavaneswaran A, Chandran V, Gladman DD. Gender difference in disease expression, radiographic damage and disability among patients with psoriatic arthritis. Ann Rheum Dis. 2013;72(4):578\u201382.","journal-title":"Ann Rheum Dis"},{"issue":"3\u20134","key":"445_CR6","first-page":"203","volume":"18","author":"E Generali","year":"2016","unstructured":"Generali E, Scir\u00e9 CA, Cantarini L, Selmi C. Sex differences in the treatment of psoriatic arthritis: a systematic literature review. Israel Med Assoc J. 2016;18(3\u20134):203\u20138.","journal-title":"Israel Med Assoc J."},{"issue":"4","key":"445_CR7","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.semarthrit.2020.05.005","volume":"50","author":"GC Wright","year":"2020","unstructured":"Wright GC, Kaine J, Deodhar A. Understanding differences between men and women with axial spondyloarthritis. Semin Arthritis Rheum. 2020;50(4):687\u201394.","journal-title":"Semin Arthritis Rheum"},{"key":"445_CR8","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/1471-2474-15-44","volume":"15","author":"K Hekmat","year":"2014","unstructured":"Hekmat K, Jacobsson LT, Nilsson J, Lindroth Y, Turesson C. Changes and sex differences in patient reported outcomes in rheumatoid factor positive RA-results from a community based study. BMC Musculoskelet Disord. 2014;15:44.","journal-title":"BMC Musculoskelet Disord"},{"issue":"6","key":"445_CR9","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1586\/1744666X.2014.905741","volume":"10","author":"L Eder","year":"2014","unstructured":"Eder L, Gladman DD. Predictors for clinical outcome in psoriatic arthritis\u2014What have we learned from cohort studies? Expert Rev Clin Immunol. 2014;10(6):763\u201370.","journal-title":"Expert Rev Clin Immunol"},{"key":"445_CR10","first-page":"1","volume":"9","author":"D Colombo","year":"2016","unstructured":"Colombo D, Chimenti S, Grossi PA, et al. Prevalence of acute and chronic viral seropositivity and characteristics of disease in patients with psoriatic arthritis treated with cyclosporine: a post hoc analysis from a sex point of view on the observational study of infectious events in psoriasis complicated by active psoriatic arthritis. Clin Cosmet Investig Dermatol. 2016;9:1\u20137.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"9","key":"445_CR11","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1093\/rheumatology\/key140","volume":"57","author":"P H\u00f8jgaard","year":"2018","unstructured":"H\u00f8jgaard P, Ballegaard C, Cordtz R, et al. Gender differences in biologic treatment outcomes-a study of 1750 patients with psoriatic arthritis using danish health care registers. Rheumatology (Oxford). 2018;57(9):1651\u201360.","journal-title":"Rheumatology (Oxford)"},{"key":"445_CR12","doi-asserted-by":"crossref","unstructured":"Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on outcome measures in rheumatoid arthritis clinical trials. Arthritis Rheum. 1993;36(6):729\u201340.","DOI":"10.1002\/art.1780360601"},{"issue":"8","key":"445_CR13","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1136\/ard.2009.122259","volume":"69","author":"M Schoels","year":"2010","unstructured":"Schoels M, Aletaha D, Funovits J, Kavanaugh A, Baker D, Smolen JS. Application of the DAREA\/DAPSA score for assessment of disease activity in psoriatic arthritis. Ann Rheum Dis. 2010;69(8):1441\u20137.","journal-title":"Ann Rheum Dis"},{"key":"445_CR14","doi-asserted-by":"crossref","unstructured":"Taylor PC, Lee YC, Fleischmann R, et al. Achieving pain control in Rheumatoid Arthritis with Baricitinib or Adalimumab plus Methotrexate: results from the RA-BEAM Trial. J Clin Med. 2019;8(6):831.","DOI":"10.3390\/jcm8060831"},{"issue":"1","key":"445_CR15","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/ard.2008.102053","volume":"69","author":"LC Coates","year":"2010","unstructured":"Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis. 2010;69(1):48\u201353.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"445_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v045.i06","volume":"45","author":"Y Yuan","year":"2011","unstructured":"Yuan Y. Multiple imputations using SAS software. J Stat Softw. 2011;45(6):1\u201325.","journal-title":"J Stat Softw"},{"key":"445_CR17","doi-asserted-by":"crossref","unstructured":"Theander E, Husmark T, Alenius GM, et al. Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA). Ann Rheum Dis. 2014;73(2):407\u201313.","DOI":"10.1136\/annrheumdis-2012-201972"},{"issue":"12","key":"445_CR18","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1002\/acr.24090","volume":"72","author":"AM Orbai","year":"2020","unstructured":"Orbai AM, Perin J, Gorlier C, et al. Determinants of patient-reported psoriatic arthritis impact of disease: an analysis of the association with sex in 458 patients from fourteen countries. Arthritis Care Res. 2020;72(12):1772\u20139.","journal-title":"Arthritis Care Res"},{"issue":"2","key":"445_CR19","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s002960100135","volume":"21","author":"R Queiro","year":"2001","unstructured":"Queiro R, Sarasqueta C, Torre JC, Tintur\u00e9 T, L\u00f3pez-Lagunas I. Comparative analysis of psoriatic spondyloarthropathy between men and women. Rheumatol Int. 2001;21(2):66\u20138.","journal-title":"Rheumatol Int"},{"issue":"4","key":"445_CR20","first-page":"371","volume":"15","author":"DD Gladman","year":"1992","unstructured":"Gladman DD, Brubacher B, Buskila D, Langevitz P, Farewell VT. Psoriatic spondyloarthropathy in men and women: a clinical, radiographic, and HLA study. Clin Invest Med. 1992;15(4):371\u20135.","journal-title":"Clin Invest Med"},{"issue":"238","key":"445_CR21","first-page":"127","volume":"62","author":"DD Gladman","year":"1987","unstructured":"Gladman DD, Shuckett R, Russell ML, Thorne JC, Schachter RK. Psoriatic arthritis (PSA)\u2014an analysis of 220 patients. Q J Med. 1987;62(238):127\u201341.","journal-title":"Q J Med"},{"key":"445_CR22","doi-asserted-by":"crossref","unstructured":"Duru\u00f6z MT, Gezer HH, Nas K, et al. Gender-related differences in disease activity and clinical features in patients with peripheral psoriatic arthritis: A multi-center study. Joint Bone Spine. 2021;88(4):105177.","DOI":"10.1016\/j.jbspin.2021.105177"},{"issue":"2","key":"445_CR23","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1002\/art.30117","volume":"63","author":"B Glintborg","year":"2011","unstructured":"Glintborg B, \u00d8stergaard M, Dreyer L, et al. Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor \u03b1 therapy: results from the nationwide Danish DANBIO registry. Arthritis Rheum. 2011;63(2):382\u201390.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"445_CR24","first-page":"681","volume":"35","author":"E Druyts","year":"2017","unstructured":"Druyts E, Palmer JB, Balijepalli C, et al. Treatment modifying factors of biologics for psoriatic arthritis: a systematic review and Bayesian meta-regression. Clin Exp Rheumatol. 2017;35(4):681\u20138.","journal-title":"Clin Exp Rheumatol"},{"key":"445_CR25","doi-asserted-by":"crossref","unstructured":"Mease PJ, Karki C, Liu M, et al. Discontinuation and switching patterns of tumour necrosis factor inhibitors (TNFis) in TNFi-naive and TNFi-experienced patients with psoriatic arthritis: an observational study from the US-based Corrona registry. RMD Open. 2019;5(1):e000880.","DOI":"10.1136\/rmdopen-2018-000880"},{"key":"445_CR26","first-page":"1832","volume":"78","author":"D Benavent","year":"2019","unstructured":"Benavent D, Plasencia C, Navarro-Comp\u00e1n V, et al. AB0736 Gender influence on treatment effectiveness in psoriatic arthritis. Ann Rheum Dis. 2019;78:1832\u20133.","journal-title":"Ann Rheum Dis"},{"key":"445_CR27","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1136\/annrheumdis-2021-eular.142","volume":"80","author":"U Kiltz","year":"2021","unstructured":"Kiltz U, Brandt-Juergens J, K\u00e4stner P, Riechers E, Peterlik D, Tony HP. POS1023 How does gender affect secukinumab treatment outcomes and retention rates in patients with psoriatic arthritis?\u2014real world data from the german aquila study. Ann Rheum Dis. 2021;80:780\u20131.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"445_CR28","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.3899\/jrheum.101142","volume":"38","author":"JA Markenson","year":"2011","unstructured":"Markenson JA, Gibofsky A, Palmer WR, et al. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry. J Rheumatol. 2011;38(7):1273\u201381.","journal-title":"J Rheumatol"},{"issue":"2","key":"445_CR29","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1002\/art.23333","volume":"59","author":"MS Heiberg","year":"2008","unstructured":"Heiberg MS, Koldingsnes W, Mikkelsen K, et al. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum. 2008;59(2):234\u201340.","journal-title":"Arthritis Rheum"},{"key":"445_CR30","unstructured":"Pavelka K, Forejtov\u00e1 S, Stolfa J, et al. Anti-TNF therapy of ankylosing spondylitis in clinical practice. Results from the Czech national registry ATTRA. Clin Exp Rheumatol. 2009;27(6):958\u201363."},{"issue":"1","key":"445_CR31","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1186\/s13075-020-02337-2","volume":"22","author":"R Neuenschwander","year":"2020","unstructured":"Neuenschwander R, Hebeisen M, Micheroli R, et al. Differences between men and women with nonradiographic axial spondyloarthritis: clinical characteristics and treatment effectiveness in a real-life prospective cohort. Arthritis Res Ther. 2020;22(1):233.","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"445_CR32","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1136\/annrheumdis-2019-215934","volume":"79","author":"R Micheroli","year":"2020","unstructured":"Micheroli R, Tellenbach C, Scherer A, et al. Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort. Ann Rheum Dis. 2020;79(9):1203\u20139.","journal-title":"Ann Rheum Dis"},{"key":"445_CR33","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/1741-7015-10-82","volume":"10","author":"N Lesuis","year":"2012","unstructured":"Lesuis N, Befrits R, Nyberg F, van Vollenhoven RF. Gender and the treatment of immune-mediated chronic inflammatory diseases: rheumatoid arthritis, inflammatory bowel disease and psoriasis: an observational study. BMC Med. 2012;10:82.","journal-title":"BMC Med"},{"issue":"7","key":"445_CR34","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1093\/rheumatology\/kez505","volume":"59","author":"F Iannone","year":"2020","unstructured":"Iannone F, Nivuori M, Fornaro M, Venerito V, Cacciapaglia F, Lopalco G. Comorbid fibromyalgia impairs the effectiveness of biologic drugs in patients with psoriatic arthritis. Rheumatology (Oxford). 2020;59(7):1599\u2013606.","journal-title":"Rheumatology (Oxford)"},{"key":"445_CR35","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/1471-2458-7-212","volume":"7","author":"A Nazmi","year":"2007","unstructured":"Nazmi A, Victora CG. Socioeconomic and racial\/ethnic differentials of C-reactive protein levels: a systematic review of population-based studies. BMC Public Health. 2007;7:212.","journal-title":"BMC Public Health"},{"issue":"6","key":"445_CR36","first-page":"317","volume":"115","author":"C Bray","year":"2016","unstructured":"Bray C, Bell LN, Liang H, et al. Erythrocyte sedimentation rate and c-reactive protein measurements and their relevance in clinical medicine. WMJ. 2016;115(6):317\u201321.","journal-title":"WMJ"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-022-00445-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-022-00445-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-022-00445-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T04:14:42Z","timestamp":1653365682000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-022-00445-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,9]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["445"],"URL":"https:\/\/doi.org\/10.1007\/s40744-022-00445-w","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,9]]},"assertion":[{"value":"21 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The studies and the Rapid Service Fee were sponsored by Eli Lilly and Company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship"}},{"value":"Lihi Eder contributed to the conception of the work, design of the work, interpretation of data for the work, and critical revision of the manuscript for important intellectual content. Hans-Peter Tony contributed to the acquisition of data for the work, interpretation of data for the work, and critical revision of the manuscript for important intellectual content. Satish Odhav, Trev Sprabery, Amanda Gellett, Clint Bertram, and Alexis Ogdie contributed to the interpretation of data for the work and critical revision of the manuscript for important intellectual content. Eva Galindez Agirregoikoa contributed to the analysis of data for the work, interpretation of data for the work, drafting of the manuscript, and critical revision of the manuscript for important intellectual content. Marius Korkosz contributed to the acquisition of data of the work and critical revision of the manuscript for important intellectual content. Sergio Schwartzman contributed to the analysis of data for the work, interpretation of data for the work, and critical revision of the manuscript for important intellectual content. So Young Park contributed to the analysis of data for the work, interpretation of data for the work, and drafting of the manuscript","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"The authors would like to thank Nicole Lipitz of Syneos Health for medical writing support, funded by Eli Lilly and Company.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Medical Writing, Editorial, and Other Assistance"}},{"value":"Lihi Eder has received unrestricted educational and research grants and consulting fees from Abbvie, Amgen, Celgene, Eli Lilly and Company, Janssen, Novartis, Pfizer, Sandoz, and UCB. Hans-Peter Tony has received payments from Eli Lilly and Company. Satish Odhav and\/or his institution has received research grants and speaking or consulting fees from Abbvie, Amgen, Astra Zeneca, Bristol Myers Squibb, Celgene, Eli Lilly and Company, Exagen, Galapagos (Gilead), GSK, Horizon, Ironwood, Janssen, Mallinckrodt, Nektar, Nichi-Iko, Novartis, Pfizer, Primus, Regeneron, Sanofi, Selecta, and UCB. Eva Galindez Agirregoikoa and Mariusz Korkosz have no payments to disclose. Sergio Schwartzman has received speaking fees from Abbvie, Genentech, Janssen, Eli Lilly and Company, Novartis, Pfizer, Regeneron, Sanofi, UCB; has stock ownership for Amgen, Boston Scientific, Gilead, Medtronic, and Pfizer; has received consulting fees from Abbvie, Crescendo, Dermtech, Janssen, Gilead, Lilly, Myriad, Novartis, Regeneron, Samsung, Sanofi, and UCB; serves as a board member of the National Psoriasis Foundation; and serves on the scientific advisory board for Myriad. Aubrey Trevelin Sprabery, Amanda M Gellett, Chen-Yen Lin, So Young Park, and Clinton C Bertram report employment with and stock ownership for Eli Lilly and Company. At the time of this publication, Amanda M Gellett is now affiliated with Sanofi Genzyme. Alexis Ogdie and\/or her institution has received grants from Amgen, Novartis, and Pfizer; has received consulting fees from Abbvie, Amgen, Bristol Myers Squibb, Celgene, Corrona, Eli Lilly and Company, Pfizer, and Novartis; has received speaking fees from Abbvie, Amgen, and Celgene; and has received royalties from Novartis.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"The SPIRIT-P1 and SPIRIT-P2 trials were conducted in accordance with the ethical principles of the Declaration of Helsinki as well as local laws and regulations. All trial participants provided written informed consent. Protocols and consent forms were approved by the institutional review board or ethics committee of each site, including the Western Institutional Review Board (SPIRIT-P1) and the Bellberry Human Research Ethics Committee (SPIRIT-P2). A listing of individual sites for the trials are included in the supplements of the primary manuscripts [, ]. Both trials were registered on ClinicalTrials.gov (SPIRIT-P1: NCT01695239, SPIRIT-P2: NCT02349295).","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethics Guidelines"}},{"value":"The datasets generated and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"An overview of preliminary results on PsA patient subgroups related to this post-hoc analysis was presented at the 2019 Annual Scientific Congress of the European League Against Rheumatism (EULAR) from June 12 through 15 in Madrid, Spain.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Prior Presentation"}}]}}